Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Wearable Health Devices: Helpful or Harmful to Our Well-Being?

by Team Lumida
January 9, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
Wearable Health Devices: Helpful or Harmful to Our Well-Being?
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • Wearable devices like the Oura Ring and Apple Watch have become essential tools for tracking health metrics such as sleep and heart rate.
  • While many find these devices motivational, doctors warn about the anxiety caused by excessive data tracking, especially for those with health anxiety.
  • The wearables industry is booming, with millions of devices sold, but experts caution that too much data can result in stress and disrupt sleep patterns.
  • Mental health experts recommend using wearables with care, suggesting taking breaks from tracking to avoid the negative effects of over-monitoring.

What Happened?
Health-tracking wearables, including devices like the Oura Ring and Apple Watch, have become mainstream, with almost half of U.S. households using some form of wearable device. These tools offer insights into sleep, exercise, heart rate, and other vital metrics. However, their widespread use has sparked concern among experts about the potential for data overload, which could lead to unnecessary anxiety and negative health impacts.

Why It Matters?
While wearables can provide valuable health insights and motivate users to adopt healthier habits, excessive data tracking can exacerbate health anxiety. Mental health professionals highlight the importance of balance and self-care when engaging with health data, suggesting that users should be mindful of how these devices affect their well-being.

What’s Next?
The wearable health-tech industry continues to grow, with leading companies like Oura and Apple pushing forward innovations to capture an even larger market. However, as more consumers track their health via these devices, experts will continue to monitor their mental and physical impacts. For users, it’s vital to strike a balance between leveraging wearable tech for health benefits and avoiding stress-induced by constant data monitoring.

Source
Previous Post

Stablecoin Transactions Surge to $33 Trillion in 2025, USDC Dominates

Next Post

Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief

Recommended For You

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
6 hours ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
1 week ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more

Nearly 90% of Americans Have It and Don’t Know It: First Guidelines Issued for CKM Syndrome

by Team Lumida
2 weeks ago
people holding us a flag during daytime

The American Heart Association and three major medical societies published the first clinical guidelines for cardiovascular-kidney-metabolic syndrome — a cluster of interconnected conditions tied to excess body fat...

Read more

Employers Are Slashing GLP-1 Coverage as Costs Spiral — And Some Are Adding Weigh-Ins to Keep It

by Team Lumida
2 weeks ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

More than a quarter of large companies are adding new criteria for GLP-1 weight-loss coverage while 11% are dropping it altogether, as drug costs balloon and employers struggle...

Read more

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
2 weeks ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Shoppers on weight-loss drugs are dropping a clothing size every month, flooding retailers with returns — one online suit seller saw a 50% jump — and forcing the...

Read more

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
1 month ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
1 month ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
1 month ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
1 month ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
2 months ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more
Next Post
Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief

Johnson & Johnson Strikes Deal with Trump for Drug Discounts and Tariff Relief

America’s Job Market Is Stalled — Low Unemployment Masks a Growing Hiring Freeze

America’s Job Market Is Stalled — Low Unemployment Masks a Growing Hiring Freeze

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan’s $3 Billion NYC Tower Signals Office Market Recovery as City Leads National Comeback

August 18, 2025
a chevron gas station at night time

Chevron Sells 70% Stake in East Texas Gas Assets for $525 Million to Optimize Portfolio

April 1, 2025
Qualcomm Wins Crucial Legal Battle Against Arm Over Nuvia License Dispute

Qualcomm to Acquire Alphawave for $2.4 Billion to Boost AI and Data Center Capabilities

June 9, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018